Drugs / BV601
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05672966 | Aug 2023 → Jul 2024 | human papilloma virus infection | Wuhan BravoVax Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BV601 | “This is a Phase I, first-in-human, randomized, observer-blinded, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and immunogenicity of BV601 (a...” NCT05672966 ↗ |
| Modality | Vaccine | “BV601 (a HPV Vaccine)” NCT05672966 ↗ |
| Route | Intramuscular | “0.5mL, Intramuscular” NCT05672966 ↗ |